Altogether, our results provide a solid rationale for the combination treatment of HDAC inhibitors with TKIs, such as crizotinib, which shifts cell cycle arrest and the differentiation phenotype toward effective tumor cell death. This evidence concerns the gene HDAC9 and neoplasm.